Mitsubishi UFJ Asset Management Co. Ltd. Lowers Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Mitsubishi UFJ Asset Management Co. Ltd. reduced its position in shares of Twist Bioscience Co. (NASDAQ:TWST) by 6.7% during the 4th quarter, HoldingsChannel reports. The firm owned 48,219 shares of the company’s stock after selling 3,485 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Twist Bioscience were worth $2,282,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in TWST. Thrivent Financial for Lutherans lifted its stake in shares of Twist Bioscience by 54.6% during the 4th quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the last quarter. State Street Corp boosted its position in shares of Twist Bioscience by 19.9% in the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock valued at $36,042,000 after acquiring an additional 521,272 shares in the last quarter. Jennison Associates LLC increased its stake in Twist Bioscience by 80.2% during the 4th quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after purchasing an additional 302,884 shares in the last quarter. Finally, American Century Companies Inc. lifted its position in Twist Bioscience by 63.5% during the 4th quarter. American Century Companies Inc. now owns 756,352 shares of the company’s stock worth $35,148,000 after acquiring an additional 293,751 shares during the period.

Insider Transactions at Twist Bioscience

In other news, Director Robert Chess sold 5,000 shares of the stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the transaction, the director now directly owns 16,641 shares in the company, valued at approximately $832,050. This represents a 23.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $43.26, for a total transaction of $254,628.36. Following the transaction, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at approximately $4,762,752.96. This trade represents a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,799 shares of company stock worth $1,593,944 in the last 90 days. Insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $38.94 on Wednesday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The business’s 50 day moving average price is $44.76 and its 200 day moving average price is $45.28. The company has a market cap of $2.32 billion, a price-to-earnings ratio of -11.52 and a beta of 2.15. Twist Bioscience Co. has a one year low of $27.41 and a one year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The firm had revenue of $88.70 million for the quarter, compared to analysts’ expectations of $86.96 million. During the same quarter in the previous year, the company posted ($0.75) EPS. The company’s revenue was up 24.1% compared to the same quarter last year. On average, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent research reports. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price on the stock. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Robert W. Baird boosted their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Finally, JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.